Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial.
Sign Up to like & getrecommendations! Published in 2024 at "European heart journal"
DOI: 10.1093/eurheartj/ehae614
Abstract: BACKGROUND AND AIMS In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce the risk of the primary endpoint through 90 days versus… read more here.
Keywords: csl112; baseline ldl; risk; aegis trial ... See more keywords